Ten patients received a loading dose of tobramycin of 60 mg/m2 intravenously over 0.5 h followed immediately by 60 mg/m2 over-2 h every 4 h. The highest mean serum concentration (at the end of the loading dose) was 6.0 0.3 ug/ml (range, 3.2 to 10.9 ,Ig/ml). The mean serum concentration 2 h after the end of the initial 2-h infusion was 3.0 ± 0.2 ug/ml (range, 1.6 to 3.9 ug/ml). This schedule of tobramycin was used to treat 117 patients with presumed or proven infection. There were no differences in the mean serum concentrations of tobramycin at comparable times on days 3 to 4 and 6 to 7. Only 60% of patients had serum levels between 3 ,ug/ml (trough) and 10 ug/ml (peak). This intermittent schedule of administration resulted in substantial fluctuations in serum concentrations of tobramycin and produced trough concentrations which were too low or peak concentrations which were too high in some patients.
Infection is the most frequent cause of morbidity and mortality in patients with malignant disease (4, 5) . Gram-negative organisms are responsible for most episodes of infection. The aminoglycoside group of antibiotics have the broadest spectrum of activity against these organiisms; however, their efficacy is diminished in neutropenic patients (1) . Various schedules of administration of aminoglycosides have been investigated. Aminoglycosides have been given by an interrupted dosage schedule at 6-to 8-h intervals which results in a high peak serum concentration, but a low serum concentration 6 to 8 h after a dose (7) . Tobramycin, gentamicin sulfate, sisomicin, and amikacin have been given by continuous infusion with a more constant serum concentration maintained throughout the period of infusion (2, 6) . 'rhe continuous infusion of aminoglycosides has the disadvantage of requiring more nursing attention and requiring one intravenous site solely for the administration of the aminoglycoside. This pharmacology study was initiated to investigate a method of interrupted aminoglycoside (tobramycin) administration which would allow the administration of other antibiotics through the same intravenous site.
MATERIALS AND METHODS
Initially, a pilot study was conducted to determine the feasibility of utilizing this new intermittent schedule. Ten patients who had metastatic cancer or leukemia and had received ablative chemotherapy (BCNU, BCNU-VP-16-cyclophosphamide, or piperazinedione) and total body irradiation followed by au- Upon completion of the pilot study, this schedule of tobramycin administration was incorporated into a therapeutic antibiotic regimen. Neutropenic (neutrophil count of sl,000/mm3) patients who developed fever (-101°F) presumed to be due to infection were entered on this study. During 358 febrile episodes, patients were randomly assigned to receive ticarcillin and tobramycin, or ticarcillin, cephalothin, and tobramycin. The dosage of drugs was: ticarciUin, 4 g in 200 ml of D5W over 2 h every 4 h; cephalothin, loading dose of 3 g in 50 ml of D5W over 30 min immediately followed by maintenance doses of 3 g in 200 ml of D5W every 6 h by continuous infuson; tobramycin, 60 mg/m2 in 50 ml of D5W over 30 min immediately followed by maintenance doses of 60 mg/M2 in 200 ml of D5W by infusion over 2 h every 4 h (total daily dose, 9.0 mg/kg per day). All patients received the 
RESULTS
The mean serum concentrations of tobramycin on days 1, 3 or 4, and 6 or 7 are shown in Fig. 1 had been administered during a 2.5-h period. On day 3 (or 4), the mean peak serum concentration obtained after completion of a 2-h infusion was 6.3 ± 0.4 ,ug/ml, and the lowest (trough) mean serum concentration was 2.9 ± 0.5 ,ug/ml. On day 7 (or 6), the comparable concentrations were 7.4 ± 0.6 ,tg/ml and 4.5 ± 0.8 ,ug/ml, respectively. The peak serum concentrations were higher on these days than on day 1 due to the residual trough concentration existing at the time of administration of the study dose. The mean serum concentrations of tobramycin were higher on the (O h) and at the end of a 2-h infusion of tobramycin on days 3 or 4, and 6 or 7 of therapy ( Table 2) . Mean serum concentrations of tobramycin were similar for patients with infection and fever of undetermined origin at all times studied. Mean preinfusion and postinfusion concentrations were similar on days 3 and 4, and 6 and 7. Table 3 indicates the proportion of patients whose serum concentrations of tobramycin were unsatisfactory. Our intention was to maintain the serum concentration about 3 ,ug/ml without the peak serum concentration exceeding 10 ltg/ ml. These serum concentrations were arbitrarily selected so that the trough serum values would exceed the minimum inhibitory concentration of most sensitive organisms and the peak serum 
